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The usefulness of griseofulvin in the treatment
of superficial fungus infections in man is well
established. Our pharmacologic knowledge of this
compound, however, lags behind our clinical
knowledge. The pharmacology of griseofulvin ad-
ministered orally to animals has been studied by
the Glaxo Laboratories group in England (1, 2, 3).
The bulk of griseofulvin given orally is excreted
from the gastrointestinal tract apparently un-
changed (2). Absorption occurs from the small in-
testine, probably the duodenum. Declining blood
griseofulvin levels at a time when substantial
amounts of the drug are still present throughout
the gut seem to indicate a self-limiting absorptive
process in the rat (2) and the cat (3). No griseo-
fulvin could be detected in the blood of rats 12
hours following an oral dose of 10 mg/rat, despite
recovery of 69 per cent of the administered ma-
terial from the gut at that time (2).
Variations of the amount of griseofulvin ab-
sorbed in different individuals might be of clinical
importance if the amount were insufficient to
eradicate the infection. Such variation seemed
likely with a drug whose absorption is known to
be limited in animals. Our initial purpose, there-
fore, was to measure the degree of variation of
serum griseofulvin levels following a standardized
oral test dose, and to compare these with values
obtained in individuals clinically unresponsive to
average therapeutic doses of griseofulvin. Simul-
taneous determinations of the in vitro sensitivity
to griseofulvin of the fungi isolated from these
same patients were performed. Thus, clinical un-
responsiveness based on actual resistance of the
organism could be detected. Such resistance has
been reported by Fisher et at. (4) and by
Miehaelides et at. (5).
A means of increasing the absorption of
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griseofulvin seemed important, particularly in
those individuals who might be unresponsive be-
cause of inadequate absorption. The solubility of
griseofulvin is limited largely to organic solvents
such as dimethylformamide and diethylether. The
absorption of Vitamin A, another fat-soluble
compound, is known to be increased by feeding
with lipid materials (6). It was predicted by
analogy that the absorption of griseofulvin could
be increased by administration in conjunction with
a meal high in fat content.
MATEEJAL5 AND METHODS
Serum griseofulvin levels were assayed by the
spectrophotofluorometric method of Bedford,
Child and Tomich (1) as adapted by Weinstein
and Blaok (7). The assay is based on maximum
fluorescence of griseofulvin at 450 mp when ex-
cited by an incident beam of 295 mp. It is a very
sensitive method, capable of detectiog sub-
microgram quantities of griseofulvin.
The oral test dose was 1.0 gm. of griseofulvin
administered in the fasting state. Blood was
obtained by venipuncture at zero, 4, 8 and 24
hours following the test dose. The blood was
clotted at room temperature, rimmed and cen-
trifuged at 3,000 rpm for 20 minutes; the serum
was pipetted off and the griseofulvio extracted
and estimated.
It is worthy of re-emphasis that contamination
by interfering fluorescent substances is an ever-
present danger. We have used a separate set of
acid-washed and ethanol-rinsed glassware
throughout the experiments. Disposable plastic
syringes (Tomac) found to be free of contaminants
were used for venipuncture.
Thirty-seven individuals were included io the
control series. Repetitive estimations were per-
formed io several of these to assure the repro-
ducibility of the test. All other medications were
withheld during the period of testing. Aspirin,
for example, may interfere with the assay, as
Marvel (8) has indicated.
Ten individuals following the standard test
were again given 1.0 gm. of griseofulvin, but after
a high fat breakfast (bacon, eggs, cream and
butter). The test was also run following high
protein, high carbohydrate and low fat meals to
rule out a nonspecific effect of other non-fatty
foods. In addition, serum griseofulvin levels were
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TABLE 1
Serum griseofulvin (pgm./ml.)
Administered in fasting state. 0.9 1.1
Administered with high fat
meal 2.0 1.9
The serum levels of 1.0 gm. of griseofulvin
administered in the fasting state and following a
high fat meal are compared.
TABLE 2
Studies of clinical resistance to griseofulvin
Griseofulvin Serum
Levels (sgm./ml.)
4 hr. 5 hr.
Fbun
(in vitro)
(pgm./ml.)
N 5J 1.201.75
1.13
1.87
5.0-8.0
M.A 1.44 1.81 2.0—3.0
J.P.M 0 — 1.6—1.8
C.W 0 .625 1.4—1.6
The serum levels of griseofalvin in five clinically
unresponsive patients are tabulated with the
in vitro sensitivity to griseofulvin of the organisms
isolated from each patient.
determined following a high fat meal with no
griseofulvin, to determine if the fatty meal itself
would influence the assay.
Higher serum levels of griseofulvin following
administration with a high fat meal could be due
either to increased absorption or to a decreased
rate of clearance from the lipidemic serum. Hence,
a two-hour intravenous infusion of fat emulsion
(Lipomul) was used to measure serum griseofulvin
clearance in the presence of hyperlipemia. Such
an experiment should result in increased griseo-
fulvin levels if the effect of high fat were based on
the delayed clearance rather than increased
absorption.
A small series of people whose dermatophytic
infections had not responded to griseofulvin in
the usual doses were studied. Fungal isolates
from these individuals were tested for in vitro
resistance by Dr. Frank J. Roth, Jr., using the
pellet implant technic (9). The oral griseofulvin
test was administered to evaluate absorption.
RESULTS
The serum griscofulvin levels at 4 and S hours
following the oral test dose administered to the 37
Fsa. 1. The serum griseofulvin levels at 4 and
8 hours following the test 1.0 gm. oral dose in 37
control individuals are depicted as average values
and the spread of these values.
controls are depicted in Figure 1. The spread of
the values is quite large, ranging from 0—3.75
mcg./ml. at 4 hours and from 0.25-3.75 meg/mI.
at 8 hours. The average values were 1.31 and 1.19
mcg./ml.
Repetitive determinations in the same indi-
viduals over a period of several months resulted
in surprisingly similar values. An example of the
reproducibility is shown in Figure 2. Persons with
high values were consistently high, and those
with low values were low each time.
A comparison of the serum griseofulvin levels in
10 subjects with and without a high fat meal are
presented in Table 1. The serum levels following
the high fat intake were approximately double
those following griseofulvin in the fasting state.
In addition (Fig. 3), one-half (0.5 gm.) of the
standard test dose administered with the high fat
meal daily over a four-day period resulted in
serum levels equivalent to those following the full
1.0 gm. dose in the fasting state. Furthermore,
the full dose plus the high fat meal resulted in ap-
proximately doubled values.
Administration of high protein or carbohydrate,
low fat meals did not increase serum levels
(Fig. 4); thus the effect is specific for fatty sub-
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FIG. 2. The reproducibility of repeated testing with the same dose of oral griseofulvin is demon-
strated.
3.0-
jsgrn/mI
s————. 1.0gm Griseafuivin paqd fasting
o •c 0.5gm Griseafulvis paqd with high fat meal
U————. 1.0gm Griseafulvin paqd with high fat meal
FIG. 3. The serum levels following a daily 1 gm.
dose of griseofulvin in the fasting state are com-
pared with 0.5 gm. and 1 gm. daily following a
high fat meal in the same individual.
stances. In the same figure, it is shown that the
degree of increased serum levels is proportional to
the amount of fat administered.
The intravenous fat infusion had no effect on
the griseofulvin levels despite a marked hyper-
lipemia at the time of blood sampling.
The data presented in Table 2 are in accord
with the two possible mechanisms of clinical un-
responsiveness. The patients noted at the top of
the table attained normal or high serum griseo-
fulvin levels. The fungus isolated from these indi-
viduals, however, exhibited definite in vitro re-
FIG. 4. This is a comparison of the effects of
dafferent types of food intake on the serum
griseofulvin levels following the 1.0 gm. oral dose.
sistance to griseofulvin (10). The two patients
noted at the bottom of the table, by contrast, had
very low serum griseofulvin values following the
test dose. Their fungus was not resistant to
griseofulvin in vitro.
DISCUSSION
The serum griseofulvin values at 4 and S hours
following the oral test dose were taken to repre-
sent an estimation of the total amount of circu-
lating griseofulvin. Integration of the area under
the total curves was discarded as meaningless
since the number and time intervals of serum
GR/SEOFULV/N SERUM LEVELS
(REPEr/r/VE DErERM/NAT/o,vS/N SAME/ND/V/DUAL)
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samples which were practical did not provide
enough points in time for an accurate curve. The
4 and 8 hour specimens give a reasonable estima-
tion of the total amount present, since the time
needed for the return of the curve to the baseline
is proportional to the peak levels thus obtained.
The remarkably wide range of serum griseo-
fulvin levels in a control series of individuals fol-
lowing the same oral test dose is probably related
to the poor solubility of griseofulvin in aqueous
media. Thus, absorption of the drug could be
altered by several local gastrointestinal factors,
such as motility, emulsification, transit time, etc.
It has been demonstrated in this report that fat
in tbe gut can increase the absorption. It is not
known whether the effect is indirectly due to a
change in motility, to stimulation of gall bladder
secretion with increased emulsification, to alter-
ation of transport mechanisms or other factors.
The increased serum levels of griseofulvin follow-
ing a high fat meal were shown to be due to in-
creased absorption rather than decreased serum
clearance rate, by comparison of levels obtained
with simultaneous intravenous fat emulsion.
The evidence to support the hypothesis tbat
poor absorption of griseofulvin migbt result in
clinical unresponsiveness to usual therapeutic
doses is firm but circumstantial. Clearing of the
lesions with the same dose by inducing greater
absorption would strengthen the case. Interest-
ingly, it has been suggested that administration
of griseofulvin in oil suspension is more effective
as therapy of experimental animal dermatophyte
infections than the same dose in aqueous form
(11). Proof of such a mechanism is dependent
upon actual estimation of griseofulvin at the
target tissue; i.e., skin, hair or nails. An assay for
griseofulvin in these tissues in man is now being
developed in this laboratory. It will then be pos-
sible to study the quantitative relationship of
tissue levels to serum levels and expand our
knowledge of the compartmental kinetics of
griscofulvin pharmacology in the human.
SUMMARY
1. Serum griseofulvin levels in humans follow-
ing a standardized oral test dose vary widely be-
tween individuals.
2. The amount of serum griseofulvin following
a test dose may be nearly doubled by administra-
tion with a high fat meal.
3. The elevated levels arc due to increased ab-
sorption of griseofulvin from the gastrointestinal
tract rather than to slowed serum clearance.
4. Evidence is presented that inadequate ab-
sorption of griseofulvin is one of the mechanisms
of clinical failure with ordinary therapeutic doses.
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DISCUSSION
Da. FREDERICK REins (New York, N. Y.): I
would like to ask two short questions:
What would he the explanation of griseofulvin-
resistant patients whose isolated fungi in vitro
studies show little resistance against griseofulvin,
because such cases have been observed?
Secondly may I ask the presenter whether
there is any difference in the absorption level be-
tween saturated and unsaturated fats?
DR. JOSEPH MCGUIRE (New Haven, Conn.):
It seems very clear from your data that one
mechanism of low griseofulvin serum levels is
poor absorption. Is it technically possible to do
griseofulvin assays on urine. I wonder if some of
these patients who are resistant to griseofulvin
are either inactivating it or excreting it faster
than normals.
DR. DONALD S. SCHUSTER (Palo Alto, Calif.):
I wonder if the authors have considered the use of
Benemid along with the administration of griseo-
fulvin in order to increase serum levels of the
drug.
Dn. ROBERT G. CROUN5E (Miami, Fla.): I
would like to thank the diseussors.
Dr. Reiss, The organism from the patient in
the center of Table 2 was inhibited in vitro by
griseofulvin concentrations of uncertain signifi-
cance. It was believed (Dr. Frank J. Roth, Jr.,
personal communication) that the normal in-
hibitory concentrations of griseofulvin in vitro
were in the range of 1.4 to 1.6 mierogm./ml. We
may have to change our interpretation of these
values on the basis of clinical studies.
The effect of saturated as contrasted with un-
saturated fats might be important. I do not in-
tend to produce coronary artery disease in the
process of treating fungus infections. We shall
study this point in the future.
Dr. MeGuire, the amount of unexehanged gris-
eofulvin excreted in the urine is said to be about
0.6 per cent of the total dose and does not corre-
lated in time with serum levels. Perhaps assay of
feces would be of more help. We have not done
this.
Dr. Schuster, the answer to your question con-
cerning Benemid is related to the previous answer.
The effect of Benemid presumably would be to
induce urinary retention. We have considered its
use but have not done so because of the small
amounts of griseofulvin normally excreted via the
urinary tract.
